Matinas BioPharma Holdings, Inc. Approved to Trade on OTCQB

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Matinas BioPharma Holdings, Inc. Approved to Trade on OTCQB Venture Stage Marketplace

BEDMINSTER, N.J., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced it has been approved to continue quotation of its securities on OTCQB, the venture stage marketplace (the "OTCQB"), effective as of September 5, 2014. The Company's shares will continue to trade under the ticker symbol "MTNB."

Roelof Rongen, President and Chief Executive Officer of Matinas BioPharma, commented, "We are extremely pleased that the OTC Markets approved our application to move from OTC Pink and continue trading on the transparent and respected OTCQB venture stage marketplace. The Company has worked diligently to continue to improve its business fundamentals and wholeheartedly supports the mission of the OTC Markets Group to provide increased transparency to investors so that they can properly analyze, value and trade their securities. We are proud to now be trading on the OTCQB with the goal of graduating to a national exchange at a future date."

The OTCQB marketplace helps investors easily identify OTC-traded companies that report to the Securities and Exchange Commission, and it has replaced OTC Bulletin Board as the standard designation for the vast majority of this category of OTC companies. Recently, OTC Markets has established new eligibility standards for companies to be able to trade on the OTCQB Marketplace. These new standards are aimed at improving information available to investors and providing a better venture stage marketplace for early and developing U.S. and international companies. Subsequent to the implementation of these new standards, new issuers were automatically placed on the OTC Pink Marketplace and those companies trading on the OTCQB who do not comply with the new procedures within the required timeframe will be downgraded to OTC Pink. 

About MAT9001

MAT9001 is a proprietary prescription-only omega-3 fatty acid-based composition, comprised of a complex mixture of omega-3 fatty acids which is under development for therapeutic applications, with severe hypertriglyceridemia (TG>500 mg/dL) as the lead indication. Based on promising early data, the Company is preparing to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) and initiate its first human study late in the third quarter/early fourth quarter 2014. The Company believes that its development program and related clinical investigations may yield an improved therapeutic profile compared to existing therapies, based on MAT9001's differentiating mechanistic features associated with its unique composition.

About Matinas BioPharma

Matinas BioPharma is a development stage biopharmaceutical company, founded in 2011, with a focus on identifying and developing novel pharmaceutical products for the treatment of abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular and metabolic diseases. Led by an experienced management team and a board of directors with a history of building pharmaceutical companies, Matinas is focused on creating the next generation of omega-3-fatty-acid-based pharmaceutical products. Our lead product, MAT9001, which takes advantage of advancements in the field of lipidomics, has been specifically designed and formulated for therapeutic applications in the dyslipidemia field. For more information, please visit www.matinasbiopharma.com .

Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could", "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of MAT9001; our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials for MAT9001; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statement to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's lead product candidate MAT9001 is in a development stage and is not available for sale or use.

Investor and Media Contact Jenene Thomas Investor Relations and Corporate Communications Advisor Jenene Thomas Communications, LLC Phone: (908) 938-1475 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 13

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
Nevada Expands Rural Youth Mental Health Access

Updated Category News Views 148

Nevada's Rural Mental Health Crisis When you're navigating the barren stretches of rural Nevada, the scenic views can be breathtaking. But for many families, finding basic services like mental health care is as challenging as striking water in the desert. Cartwheel Care has taken the bull by the horns with their latest initiative to bridge this glaring gap. Partnering...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 221

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 199

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 39

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 67

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 278

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 106

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 53

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 83

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading

Top 5 Most Recently Viewed Articles

boberdoo Launches Dynamic Consent for Enhanced User Privacy

Updated Category News Views 92

boberdoo's Innovative Approach to One-to-One Consent boberdoo is making waves with its Dynamic Consent solution, a vital tool for businesses looking to comply with the FCC's one-to-one consent regulation. This live solution has been available since May 2024 and is designed to enhance transparency in lead generation by allowing consumers to have a voice in which companies...

Continue Reading
Understanding the Recent Private Student Loan Trends and Insights

Updated Category News Views 254

Overview of Recent Trends in Private Student Loans In the recent semi-annual Private Student Loan Report released by Enterval Analytics, insights into the current status of private student loans reveal a stable repayment landscape. Since Enterval focuses on the private student loan market, their findings shed light on how borrowers are adapting their financial strategies...

Continue Reading
Kyocera Unveils Exclusive Knife Set Celebrating 40 Years of Innovation

Updated Category News Views 62

Kyocera celebrated four decades of pushing boundaries in ceramic cutlery, revealing an exclusive two-piece knife set designed for both chefs and home cooks. The knives—a 4.5-inch Utility and a 5.5-inch Santoku—come dressed in vibrant Aegean Blue or Botanical Green and carry a price tag of $85. This limited-edition release is set to hit select retailers by late fall...

Continue Reading
PTC Plans Conference Call for Upcoming Fiscal Q1 Results

Updated Category News Views 145

PTC to Hold Fiscal Q1 Conference Call Boston, January 2026 — PTC (NASDAQ: PTC) is gearing up to unveil its financial performance for the first quarter of fiscal year 2026 on February 4. Investors and interested parties are invited to join a conference call and webcast at 5 PM Eastern Time, right after the stock market closes. This event will provide valuable insights...

Continue Reading
Moke America Unveils Enhanced Electric Street Vehicle for All

Updated Category News Views 282

Introducing the New Electric Street-Legal Moke Moke America, the beloved electric vehicle manufacturer, has taken a bold step forward with the launch of its latest street-legal Moke. Previously classified as a Low Speed Vehicle, this newly upgraded Moke can now reach an impressive top speed of 45 MPH, transforming the driving experience into something truly exhilarating....

Continue Reading